Translink Corporate Finance announces the IPO of FIT Biotech Oy, a Finnish biopharma company which develops and licenses its proprietary, patented Gene Transport Unit (GTU®) vector technology for new generation medical treatments. GTU is a gene transport technology that solves medical challenges in usability of gene therapy based treatments and DNA vaccines.

In the IPO, the Company raised ca. 3.5 million euros and strengthened its financial position by converting debt and interest liabilities to equity worth of ca. 13.2 million euros.

Translink Corporate Finance acted as a financial advisor and Certified Advisor, required by First North market, for FIT Biotech.

The Company’s CEO, Kalevi Reijonen, gave the following comments on the IPO: “Thanks to the funds raised in the initial public offering and the strengthening of the balance sheet through the offering, the company is now well positioned to implement its business plan in accordance with the targets we have set. We would like to thank the investors for the confidence they have shown in us.”